



# French Biocluster Genopole: 20-year expertise and international implementation.

**Genopole - France's leading biocluster - is a dynamic ecosystem where public and private synergies are cultivated to yield tomorrow's scientific and industrial breakthroughs in biotech. This cluster will celebrate its 20th birthday and attend BIO International Convention on June 4-7, 2018 in Boston, booth #527.**

## Focus on Genopole

Located in southern Paris, this French biocluster has been specializing on **genetic research** and **applied biotechnology** in health and environmental areas for 20 years.

**Genopole** clusters a total of 19 research labs, 86 biotech companies, and diverse university groups - currently covering 10 hectares of land with an incubator, modular spaces to rent together with lab buildings. **Illumina**, one of the biotech companies, recently deployed its first commercial & customer training center in Europe in order to provide demonstrations, instruction, and education in the latest genomics technologies. Their first commercial office in Europe will provide a strong support in the development of skills for the expanding genomics industry in France.

## Strategic orientations leading to tomorrow's medicine

Among **European's top three** in high throughput sequencing, Genopole aims to be a major player in tomorrow's "4Ps" medicine (Predictive, Personalized, Preventive and Participatory). The **National Center of Human Genomics Research** (*settled on Genopole's biocluster*) will soon be home to **CReflIX**, a center of reference, innovation, expertise and transfer, which is part of its Genomic Medicine France 2025 plan.

With these goals in mind, Genopole **looks to strengthen its assets in gene and cell therapies** with an eye to developing innovative medicines.

## International positioning

Genopole's strategic plan for 2025 focuses on its internationalization in order to **attract foreign talents** thanks to major global initiatives:

<b>French Tech Visa</b>	Aims to simplify international tech talents' hiring process.
<b>Néomed</b> (BIO 2017)	Signed agreement with Quebec cluster Neomed in order to boost their exchanges.
<b>Genome Québec</b>	Allows to share know-how, expertise and create a platform to connect the two organizations' academic and private partners.



Moreover, a [monthly newsletter](#) features Genopole's (and its companies) latest headlines on an international scale. The cluster does not only target North America, it also successfully acquired allies and business partners in China with a recent contract signed in [Wuhan](#) to create synergies on biotechnologies.

## Focus on BIO 2018 Convention

Genopole will exhibit on the French Pavillon, booth #527, to promote the cluster as a strategic anchor for the **commercial deployment on the European continent** and showcase five companies:

<b>Algentech</b>	Algentech develops and commercializes plant <b>gene editing technologies</b> for industrial and research applications. The proprietary technologies form unique tools for precise engineering of nuclear and organelle (chloroplast and mitochondria) genomes with multi-sectorial applications.
<b>Endiodag</b>	Develops new <b>endometriosis diagnostic solutions</b> for healthcare professionals. These solutions are intended to contribute to a better endometriosis diagnosis, a more personalized patient management, more efficient treatment options and fertility strategy.
<b>Enterome</b>	Enterome is pioneering the development of novel pharmaceuticals and diagnostics to support <b>personalized therapies in microbiome-related diseases</b> such as Inflammatory Bowel Disease (IBD) and cancer. It is also leading the development of new industry standards in <b>gut microbiome</b> quantitative and functional analysis.
<b>PEP-Therapy</b>	Aims to develop an innovative <b>anti-cancer peptide</b> , firstly for the treatment of triple-negative breast cancer and its companion <b>biomarker</b> together with the prediction of treatment efficacy.
<b>Yposkesi</b>	Yposkesi is a European industrial leader in <b>Gene and Cell Therapy</b> . Its mission is to develop, manufacture and make treatments available to patients affected by rare diseases.

Furthermore, during the event, Genopole will **launch** its third edition of:

- The **Shaker Biotech Lab** to offer tailor-made solutions to doctoral or Ph.D. students, but also young engineers who have developed an innovative concept in the field of biotechnology.
- The **Booster Business Accelerator**: a strong business-oriented support system entirely dedicated to biotech innovation.

### Meet & Greet

Genopole's representatives welcome you on their stand (#527) on Business France's French Pavilion for a **special cheese and wine tasting on June 5th, 5 pm.**

### PRESS CONTACTS

EVE GESBERT, Communications Manager North America - [eve.gesbert@businessfrance.fr](mailto:eve.gesbert@businessfrance.fr)

SANDRINE RUBIO, Project manager – [sandrine.rubio@genopole.fr](mailto:sandrine.rubio@genopole.fr)



## ABOUT GENOPOLE

As the first French biocluster dedicated to genetic research and applied biotechnology in the health and environmental areas, Genopole unites 19 research entities, 86 biotech firms, and university groups (University of Évry-Val-d'Essonne). Its goals are to foster and develop research in genomics, post-genomics and associated sciences, technology transfer to the industrial sector and high-level instruction to serve those goals, and furthermore to create and support biotech companies. Genopole is supported by the French government, the Ile-de-France Regional Council, the Essonne Departmental Council, the Grand Paris-Sud Metropolitan Area, the town of Évry and the AFM-Téléthon.

